$170.02▾ 6.06%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 253% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Repligen Corporation's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days3 articles
3 bullish0 neutral0 bearish
Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?